| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
|
(Dollars in billions, except per share data) |
||||||||||
|
Previous |
Updated |
Invitae Impact |
||||||||
|
Results |
2024 Guidance |
2024 Guidance |
In Guidance |
|||||||
|
2023 |
Low |
High |
Low |
High |
at Midpoint |
|||||
|
Revenue |
||||||||||
|
Labcorp Enterprise (1)(2) |
$12.2 |
4.8 % |
6.4 % |
6.4 % |
7.5 % |
1.0 % |
||||
|
Diagnostics Laboratories |
$9.4 |
4.8 % |
6.0 % |
6.9 % |
7.9 % |
1.3 % |
||||
|
Biopharma Laboratory Services (3) |
$2.8 |
3.7 % |
5.7 % |
3.7 % |
5.0 % |
|||||
|
Adjusted EPS |
$13.56 |
$14.45 |
$15.35 |
$14.30 |
$14.90 |
($0.40) |
||||
|
Free Cash Flow from Cont. Ops(4) |
$0.89 |
$1.00 |
$1.15 |
$0.85 |
$1.00 |
($0.15) |
||||
Posted In: LH
